Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
Tirzepatide (Zepbound) A New Treatment for Obstructive Sleep Apnea and Obesity In December 2024, the FDA approved Tirzepatide (Zepbound) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity
Immunobiotic bacteria attenuate hepatic fibrosis through the modulation of gut microbiota and the activation of aryl-hydrocarbon receptors pathway in non-alcoholic steatohepatitis mice
MRL /lpr mice (n = 6) were treated with DMSO (0.1 ml 10%), LPX-1(10 mg/kg) or CTX (20 mg/kg) every other day at week 12 for 6 weeks, DMSO (0.1 ml 10%) was applied to sex-matched MRL/Mpj mice (n = 5) as control
Nonclinical Observations Repeat-dose animal studies reported reduced food intake and body-weight changes consistent with GLP-1 receptor agonism Rodent studies identified dose-dependent thyroid C-cell hyperplasia and embryo-fetal toxicity at relevant exposures, informing laboratory hazard assessments
Intermittent fasting is often promoted as a method for losing weight and improving metabolic health
US$ 28.47
US$ 26.79
US$ 26.73
US$ 21.82
US$ 22.64
US$ 27.73
